The Pharmaceuticals and Medical Devices Agency (PMDA) announced that the SHINSA companion diagnostic (CDx) has received approval for use in identifying patients who are eligible for certain treatments. The approval was updated on June 16, 2026. Further details are available on the PMDA website.
Regulatorische Updates23. Aug. 2026•1 Min. Lesezeit
PMDA Approves SHINSA CDx for Identifying Eligible Patients
Japan’s PMDA has approved the SHINSA companion diagnostic (CDx) to help identify patients eligible for specific therapies, updated June 16, 2026.
Zusammengestellt vom PharmaCountry-Team · Quelle: PMDA Japan
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen